A Congressional committee plans to subpoena AbbVie (ABBV) for documents about pricing practices for two of its best-selling medicines, after the drug maker failed to provide information lawmakers requested when an investigation was launched in January 2019.
At the time, the House Committee on Oversight and Reform sought data from a dozen large pharmaceutical companies about their pricing tactics for some of the most expensive medicines in response to nationwide angst over the rising cost of prescription drugs. AbbVie was asked for information about Humira, its rheumatoid arthritis treatment, and Imbruvica, a medication for lymphoma.
“After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the Committee’s investigation,” Rep. Carolyn Maloney (D-NY), chair of the committee, wrote in a memo to committee members explaining why a subpoena is being sought.
About the Author Reprints
